The FDA Approved Four More Nicotine Pouches This Week. Teen Use Already Nearly Quadrupled Without Them.

A can of Zyn costs about what a coffee does, fits flat in a back pocket, and leaves no smoke, no smell, no vape cloud for a teacher to catch. That’s the whole design. It’s also why nicotine pouch use among youth and young adults nearly quadrupled between 2022 and 2025, according to the CDC Foundation’s TEEN+ Study, a national tracking project following more than 10,000 young people. On August 4, in the same stretch of news cycle as that data, the FDA authorized four more nicotine pouch products for sale.

A regulatory pathway built to help adult smokers quit combustible cigarettes is now authorizing new nicotine pouches at the exact moment the youth-use data shows the wheels have already come off — and nobody in that pathway is required to weigh the second fact against the first.

The Growth Curve Nobody Can Call Surprising

Pouches — powdered nicotine, no tobacco leaf, tucked between lip and gum — absorb straight through the mouth’s lining. No lighter, no combustion, no cough. That’s the appeal and the problem: nicotine still hits the same dopamine reward circuit, faster in a teenage brain whose prefrontal cortex — the part that weighs “not now” against “want it now” — isn’t finished developing until the mid-20s. Pouches were the second most commonly used tobacco product among youth in 2024, trailing only e-cigarettes, and Zyn alone accounted for 84.3% of pouches used by people who’d tried one in the past month. This is the fastest-growing nicotine product in the country: the CDC Foundation’s own sales data shows U.S. pouch sales up 250.8% between January 2023 and August 2025.

What “Harm Reduction” Actually Means Here

The FDA’s four newest approvals — Rich Berry, two Cappuccino strengths, and Autumn Spice, made by Helix Innovations — went through the Premarket Tobacco Product Application, or PMTA, pathway: the review a company clears before selling a new nicotine product, where the agency asks whether it’s a better option than what a smoker would otherwise reach for. That’s now 30 pouch products cleared this way. The FDA’s case is narrow and, on its own terms, reasonable: someone who fully switches from cigarettes to a pouch trades combustion for fewer harmful chemicals. The problem is that “fully switches from cigarettes” describes almost none of the teenagers picking these up — most never smoked a cigarette to begin with. The pathway wasn’t built to ask who’s actually buying.

The Marketing Isn’t Chasing the Data. It’s Ahead of It.

If you started with a pouch because a video made it look like focus, not nicotine — a jaw set, a confident cut, a can flipped between two fingers like a fidget toy — you weren’t an accident of the algorithm. The World Health Organization documented exactly that playbook in May: bubble-gum and candy flavors, influencer promotion, sponsorships at concerts and Formula 1 races, branding built around sharpness and confidence, even messaging coaching users on concealing pouches in school. Global sales hit 23 billion units in 2024, up more than 50% in a year, and the WHO notes roughly 160 countries have no pouch-specific rules at all. That gap is the whole strategy.

Nicotine replacement therapy — the patch, the gum, the lozenge — still works exactly the way it did before any of this data landed, and a pediatrician can still prescribe cessation support to a teenager today, no PMTA required.

Harm reduction for a forty-year-old pack-a-day smoker and harm reduction for a fifteen-year-old who’s never touched a cigarette are not the same policy question, no matter how many products clear the same review stamp.